| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050270A1 Novel tissue-specific secretory polypeptide and dna thereof |
| 06/27/2002 | WO2002050115A1 Modified tachykinin receptors |
| 06/27/2002 | WO2002050107A2 Streptococcus pyogenes antigens and corresponding dna fragments |
| 06/27/2002 | WO2002050101A1 Retinoblastoma-binding protein |
| 06/27/2002 | WO2002050097A2 Anti-allergic complex molecules |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050064A1 Substituted pyrrolidines as ccr-3 receptor antagonists |
| 06/27/2002 | WO2002050043A1 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof |
| 06/27/2002 | WO2002050034A2 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050030A2 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| 06/27/2002 | WO2002050029A2 Tetracyclic derivatives as spla2 inhibitors |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049651A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049625A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | WO2002049624A2 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists |
| 06/27/2002 | WO2002049616A1 Pharmaceutical aerosol formulation |
| 06/27/2002 | WO2002030390A3 Method for producing powdery formulations |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002022592A3 Substituted urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002022168A3 Vaccine against streptococcus pneumoniae |
| 06/27/2002 | WO2002022167A3 Vaccine against streptococcus penumoniae |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2001096298A3 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase |
| 06/27/2002 | WO2001093878A8 Bismuth compounds for the treatment and prevention of mucositis |
| 06/27/2002 | WO2001093853A8 Management of snoring by oral administration of dimethyl sulfone |
| 06/27/2002 | WO2001092267A3 Dihydropyridine compounds for the inhibition of calcium-influx |
| 06/27/2002 | WO2001087938A3 Polynucleotide sequence encoding a putative cell adhesion molecule |
| 06/27/2002 | WO2001077375A3 Diagnosis of diseases associated with gene regulation |
| 06/27/2002 | WO2001076600A3 Inhibition of cytokine generation |
| 06/27/2002 | US20020082435 For use in cancer therapy |
| 06/27/2002 | US20020082420 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| 06/27/2002 | US20020082417 Compound for use in the treatment of vision defects and chronic obstructive pulmonary diseases |
| 06/27/2002 | US20020082307 Useful for therapy of symptoms associated with respiratory illnesses |
| 06/27/2002 | US20020082305 Petrolatum-based nose ointment |
| 06/27/2002 | US20020082278 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases |
| 06/27/2002 | US20020082272 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 06/27/2002 | US20020082271 Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| 06/27/2002 | US20020082269 Purine-2,6-dione based compounds as receptor binding assay probes and pharmaceuticals; high potency and affinity with water solubility |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082265 For treating or preventing emphysema, cancer and dermatological disorders |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082255 Substituted ureas |
| 06/27/2002 | US20020082231 Utilizing ratC polypeptides to screen for antibacterial compounds |
| 06/27/2002 | US20020082230 Introducing an antisense oligomer into a cell, allowing the oligomer to hybridize to the mRNA of IL-15, thereby inhibiting the production of IL-15 |
| 06/27/2002 | US20020082226 Antisense antibacterial method and composition |
| 06/27/2002 | US20020082214 Alpha 1-antitrypsin preparation as well as a method for producing the same |
| 06/27/2002 | US20020082032 Access parameter adaptation and packet data resource management using detailed mobile status information |
| 06/27/2002 | US20020081682 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of bacterial infections |
| 06/27/2002 | US20020081623 Chemotactic cytokine |
| 06/27/2002 | US20020081607 Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies |
| 06/27/2002 | US20020081340 Side-effect reduction of anti-cancer therapy |
| 06/27/2002 | US20020081290 Protein kinase homologs |
| 06/27/2002 | US20020078948 Method for generating an aerosol |
| 06/27/2002 | CA2789252A1 Streptococcus pyogenes antigens and corresponding dna fragments |
| 06/27/2002 | CA2433018A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | CA2432908A1 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | CA2432879A1 Anti-allergic complex molecules |
| 06/27/2002 | CA2432762A1 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 06/27/2002 | CA2432638A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | CA2432315A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | CA2432282A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | CA2431767A1 Substituted pyrrolidines as ccr-3 receptor antagonists |
| 06/27/2002 | CA2431721A1 Tetracyclic derivatives as spla2 inhibitors |
| 06/27/2002 | CA2431147A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | CA2431139A1 Oxidoreductases |
| 06/27/2002 | CA2431077A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | CA2431074A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1) |
| 06/27/2002 | CA2431028A1 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | CA2431023A1 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | CA2430973A1 Multifunctional protease inhibitors and their use in treatment of disease |
| 06/27/2002 | CA2430918A1 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 06/27/2002 | CA2430808A1 Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
| 06/27/2002 | CA2430595A1 Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect |
| 06/26/2002 | EP1217000A1 Inhibitors of factor Xa and factor VIIa |
| 06/26/2002 | EP1216257A1 Compounds for the treatment of ischemia |
| 06/26/2002 | EP1216248A2 Triazolopyrimidine derivatives |
| 06/26/2002 | EP1216247A1 Imidazoimidazoles and triazoles as anti-inflammatory agents |
| 06/26/2002 | EP1216245A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 06/26/2002 | EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216236A1 Tryptase inhibitors |
| 06/26/2002 | EP1216052A1 Combination of c1-inh and lung surfactant for the treatment of respiratory disorders |
| 06/26/2002 | EP1216050A2 Compositions for reducing sympathomimetic-induced side effects by serenoa repens extract |
| 06/26/2002 | EP1216047A2 Novel combination of loteprednol and beta2-adrenoceptor agonists |
| 06/26/2002 | EP1216046A2 Novel combination of loteprednol and antihistamines |
| 06/26/2002 | EP1216044A1 Compositions having improved stability |